糖尿病肾病中的新兴生物标志物与创新治疗策略：精准医学之路
Emerging Biomarkers and Innovative Therapeutic Strategies in Diabetic Kidney Disease: A Pathway to Precision Medicine.
作者信息
Shetty Sahana, Suvarna Renuka, Awasthi Avivar, Bhojaraja Mohan V, Pappachan Joseph M
机构信息
Department of Endocrinology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal 576104, India.
Department of Nephrology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal 576104, India.
出版信息
Diagnostics (Basel). 2025 Apr 11;15(8):973. doi: 10.3390/diagnostics15080973.
Diabetes mellitus (DM) has emerged as the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally in recent years. Diabetic nephropathy (DN), or diabetic kidney disease (DKD) that occurs as a direct consequence of DM, has complex pathophysiological mechanisms, such as various inflammatory processes and genetic and epigenetic factors, often accentuated by comorbid illnesses like hypertension and dyslipidemia. Therefore, management of DKD involves targeting these etio-pathological processes. Various medications with remarkable disease modifying properties have been introduced for treatment of DN in recent years. We update the current and future diagnostic and therapeutic landscapes against DKD in this article.
近年来，糖尿病已成为全球慢性肾脏病（CKD）和终末期肾病（ESRD）的最常见病因。糖尿病肾病（DN），即作为糖尿病直接后果而发生的糖尿病性肾脏疾病（DKD），具有复杂的病理生理机制，如各种炎症过程以及遗传和表观遗传因素，这些因素常因高血压和血脂异常等合并症而加剧。因此，DKD的管理涉及针对这些病因病理过程。近年来，已引入了各种具有显著疾病修饰特性的药物用于治疗DN。在本文中，我们更新了针对DKD的当前和未来诊断与治疗前景。
Zotero 插件